Other

Beth Israel Deaconess Medical Center, Inc.

Mersana Therapeutics, Inc.

Simon C Robson

David R Elmaleh

Mikhail I Papisov

Todd D Giorgio

Fritz H Bach

George L Zorn, Iii

Mikhail L Papisov

Pascal O Berberat

Richard N Pierson, Iii

Agnes M Azimzadeh

The present invention relates to the treatment of disorders using heme oxygenase-1 and heme degradation products.

Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation

Biologically active agents covalently linked to a polymer. The polymer is preferably a biodegradable polymer are provided. The biologically active agent is preferably a protein, such as an extracellular soluble protein, e.g., an extracellular enzyme. The enzyme can be an apyrase, e.g., NTPDase. Conjugates of the invention can be used as therapeutics in subjects. For example, a conjugate comprising an apyrase can be used for treating and preventing thrombosis, atherosclerotic plaque complications and vascular disorders.

Conjugates comprising a biodegradable polymer and uses therefor

A method of inhibiting complement activation, particularly by a transplanted tissue, in a warm-blooded vertebrate. The method includes administering a therapeutically effective amount of a platelet activity modulator to a warm-blooded vertebrate before, during or after a tissue is transplanted to the warm-blooded vertebrate, whereby complement activation by the transplanted tissue is inhibited. The platelet activity modulator can include a combination of a GPIb modulator and a GPIIb/GPIIIa modulator.

Method for inhibiting complement activation

Growing community of inventors

Weston, MA, United States of America

Simon C Robson